Clinical Trials Browser

INDUSTRY × Lymphoma × acalabrutinib × Clear all

NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Phase 2 Completed

48 enrolled 12 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05951959 2025-10-21

TrAVeRse

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Mantle-Cell

NCT04662255 2025-05-28

BRUIN-MCL-321

Phase 3 Active not recruiting

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02112526 2024-12-20

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Phase 1 Completed

21 enrolled 11 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Large B-Cell, Diffuse